US35104E1001
US35104E1001
4D Molecular Therapeutics, Inc.
Loading chart...
Financials
Updating data...
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Updating data...
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 85.209.000 | 37.000 | 230194.6% |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 244.756.000 | 187.878.000 | 30.3% | |
| Operating Income | -159.547.000 | -187.841.000 | 15.1% |
| Pretax Income | -140.109.000 | -160.868.000 | 12.9% |
| Net Income Common Stockholders | -140.109.000 | -160.868.000 | 12.9% |
| -- | -- | -- | |
| -- | -- | -- |